Drug-induced Retinal Vein Occlusion: a Disproportionality Analysis from the FDA Adverse Event Reporting System (2004-2023)

Overview

Journal Front Pharmacol

Date 2024 Dec 30

PMID 39734405

Authors

Xiao-Dong Chen

Kun-Hong Xiao

Chao-Bing Zhou

Affiliations

Soon will be listed here.

Abstract

Introduction: Retinal vein occlusion (RVO) often causes irreversible visual impairment, making early prevention crucial. This study aims to identify associations between different medications and RVO and provide information for clinical practice.

Method: This study included reports of RVO from the FDA Adverse Event Reporting System (FAERS) database from the first quarter (Q1) of 2004 to the fourth quarter (Q4) of 2023. The reported drugs were analyzed for adverse drug reaction (ADR) signals using four disproportionality algorithms. Kaplan-Meier curves and median time to onset were used to evaluate the drugs.

Results: From 2004 to 2023, the FAERS database recorded 6,151 reports associated with RVO. Disproportionality analyses identified 25 drugs significantly associated with RVO. Mirabegron showed the highest risk signal, followed by Raloxifene, Tadalafil, Fingolimod, and Bimatoprost. These high-risk drugs are distributed across different therapeutic areas, including urogenital system and sex hormones, ophthalmic drugs, nervous system drugs, musculoskeletal system drugs, anti-tumor and immune-modulating drugs, and anti-parasitic drugs. Specific drug targets such as adrenergic receptor agonists, hormone regulators, and PDE5 inhibitors were identified as high risk. Ophthalmic drugs exhibited the longest median time to adverse ocular reactions at 532.01 days, followed by anti-parasitic drugs, nervous system drugs, urogenital system and sex hormone drugs, anti-tumor and immune-modulating drugs, and musculoskeletal system drugs.

Conclusion: This study provides an overview of drug-induced RVO, identifying potential culprit drugs and their distribution characteristics. These findings enhance understanding of medication safety and help optimize clinical practice.

Citing Articles

Risk of drug-induced pericardial effusion: a disproportionality analysis of the FAERS database.

Ren G, Huang P, Ding Y, Ma X BMC Pharmacol Toxicol. 2025; 26(1):27.

PMID: 39920868 PMC: 11806542. DOI: 10.1186/s40360-025-00867-6.

References

Montastruc J, Sommet A, Lacroix I, Olivier P, Durrieu G, Damase-Michel C . Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine. 2006; 73(6):629-32. DOI: 10.1016/j.jbspin.2006.09.002. View

Lee M, Kim B, Han K, Lee J, Kim M, Kim M . Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score-Matched Cohort Study. Diabetes Care. 2021; . DOI: 10.2337/dc20-3133. View

Findling R, Robb A, Nyilas M, Forbes R, Jin N, Ivanova S . A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008; 165(11):1432-41. DOI: 10.1176/appi.ajp.2008.07061035. View

Jiang Y, Zhou L, Shen Y, Zhou Q, Ji Y, Zhu H . Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database. J Affect Disord. 2023; 346:223-229. DOI: 10.1016/j.jad.2023.11.025. View

Li D, Wang H, Qin C, Du D, Wang Y, Du Q . Drug-Induced Acute Pancreatitis: A Real-World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database. Clin Pharmacol Ther. 2023; 115(3):535-544. DOI: 10.1002/cpt.3139. View

Kotyla P, Engelmann M, Giemza-Stoklosa J, Wnuk B, Islam M . Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?. Int J Mol Sci. 2021; 22(5). PMC: 7957632. DOI: 10.3390/ijms22052449. View

Brown E, Wood L, Wood S . The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999; 20(2):109-17. DOI: 10.2165/00002018-199920020-00002. View

Faure C, Audo I, Zeitz C, Letessier J, Robert M . Aripiprazole-induced chorioretinopathy: multimodal imaging and electrophysiological features. Doc Ophthalmol. 2015; 131(1):35-41. DOI: 10.1007/s10633-015-9494-x. View

Hayreh S . Photocoagulation for retinal vein occlusion. Prog Retin Eye Res. 2021; 85:100964. DOI: 10.1016/j.preteyeres.2021.100964. View

10.

Etminan M, Sodhi M, Mikelberg F, Maberley D . Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US. JAMA Ophthalmol. 2022; 140(5):480-484. PMC: 8990352. DOI: 10.1001/jamaophthalmol.2022.0663. View

11.

Yusuf I, Lotery A, Ardern-Jones M . Joint recommendations for retinal screening in long-term users of hydroxychloroquine and chloroquine in the United Kingdom, 2018. Br J Dermatol. 2018; 179(4):995-996. DOI: 10.1111/bjd.16782. View

12.

Yu R, Krantz M, Phillips E, Stone Jr C . Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS). J Allergy Clin Immunol Pract. 2020; 9(2):819-829.e2. PMC: 7870524. DOI: 10.1016/j.jaip.2020.09.021. View

13.

Schmidt-Erfurth U, Garcia-Arumi J, Gerendas B, Midena E, Sivaprasad S, Tadayoni R . Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019; 242(3):123-162. DOI: 10.1159/000502041. View

14.

Wishart D, Feunang Y, Guo A, Lo E, Marcu A, Grant J . DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017; 46(D1):D1074-D1082. PMC: 5753335. DOI: 10.1093/nar/gkx1037. View

15.

Liu C, Francis J, Brodie S, Marr B, Pulido J, Marmor M . Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies. Retina. 2014; 34(7):1261-80. DOI: 10.1097/IAE.0000000000000242. View

16.

Wu S, Chen X, Yan D, Wang Y, Wang S, Guan W . Drug-associated glaucoma: A real-world study based on the Food and Drug Administration adverse event reporting system database. Clin Exp Ophthalmol. 2024; 53(2):140-160. DOI: 10.1111/ceo.14454. View

17.

Zhao J, Tao Y . Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system. Front Pharmacol. 2024; 15:1393940. PMC: 11341477. DOI: 10.3389/fphar.2024.1393940. View

18.

Herschorn S, Staskin D, Schermer C, Kristy R, Wagg A . Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet. Drugs Aging. 2020; 37(9):665-676. PMC: 7473960. DOI: 10.1007/s40266-020-00783-w. View

19.

Angamo M, Chalmers L, Curtain C, Bereznicki L . Adverse-Drug-Reaction-Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence and Contributing Factors. Drug Saf. 2016; 39(9):847-57. DOI: 10.1007/s40264-016-0444-7. View

20.

Chen Y, Du Y, Qiu L, Zheng J . Central retinal vein occlusion with cerebral infarction secondary to anlotinib treatment: a case report and literature review. Front Pharmacol. 2023; 14:1188218. PMC: 10293757. DOI: 10.3389/fphar.2023.1188218. View